ViroPharma - Comparative Multiple Analysis

ViroPharma (Comparative Multiple Analysis)

Home Comparative Index ViroPharma

►Summary | Profile | News | Chart | SWOT | Cash Flow | Comps | Buffett | WACC

Link to services page

placeholder_large_analysis.png

Improve your investment analysis with by seeing the ViroPharma's Discounted Cash Flow analysis, ViroPharma's Warren Buffet analysis, and ViroPharma's Weighted Average Cost of Capital (WACC) Analysis.

Notes on the Comparative Multiple Analysis of ViroPharma

WikiWealth compares ViroPharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with ViroPharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for ViroPharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to ViroPharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for ViroPharma's Analysis


How does this work? The Comparative Investment Analysis determines the value of ViroPharma by comparing ViroPharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of ViroPharma.

See the ViroPharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in ViroPharma.

Also, see the ViroPharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and ViroPharma's valuation conclusion for a quick summary.